Epidemiology and Treatment of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis in Germany: A Real-World Evidence Study. [PDF]
Grellmann C +5 more
europepmc +1 more source
Topical Cycling and Systemic Eligibility in Patients With Psoriasis in Japan
ABSTRACT Topical therapy is the typical first‐line treatment for psoriasis, with the International Psoriasis Council recommending systemic therapy for patients with body surface area > 10%, high‐impact site involvement, or topical therapy failure. A recent Japanese Delphi Consensus Study proposed a definition for topical failure that considers time on ...
Akimichi Morita +6 more
wiley +1 more source
Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study. [PDF]
Stouten V +9 more
europepmc +1 more source
ABSTRACT Systemic psoriasis treatment options have rapidly expanded in Japan, including the approval of tyrosine kinase 2 and interleukin‐36 receptor inhibitors in 2022. However, contemporary real‐world treatment patterns across plaque, erythrodermic, and generalized pustular psoriasis remain incompletely characterized.
Yayoi Tada +9 more
wiley +1 more source
Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. [PDF]
Burmester GR +9 more
europepmc +1 more source
Redefining “Comorbidity” in Dermatology: Beyond Terminology, Lessons From Other Specialties
JEADV Clinical Practice, EarlyView.
Patricia Garbayo‐Salmons +1 more
wiley +1 more source
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter +20 more
wiley +1 more source
Safety of Venom Immunotherapy in Pregnancy: A Multicentre Study
Venom immunotherapy (VIT) during pregnancy, when maintenance dose is well tolerated, can be continued. No increased risk of adverse effects to VIT or safety concerns for the pregnancy or the newborns were observed. No decreased efficacy of VIT, in case of re‐stings, was reported.
Matteo Martini +20 more
wiley +1 more source
Psoriatic arthritis mutilans [PDF]
J Samanta, A Chattopadhyay, A Sharma
openaire +2 more sources

